172 related articles for article (PubMed ID: 31454563)
1. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?
Panza F; Lozupone M; Bellomo A; Imbimbo BP
Ageing Res Rev; 2019 Nov; 55():100948. PubMed ID: 31454563
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
[TBL] [Abstract][Full Text] [Related]
4. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
Cho JE; Kim JR
Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
[TBL] [Abstract][Full Text] [Related]
5. OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice.
Yuan C; Guo X; Zhou Q; Du F; Jiang W; Zhou X; Liu P; Chi T; Ji X; Gao J; Chen C; Lang H; Xu J; Liu D; Yang Y; Qiu S; Tang X; Chen G; Zou L
Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):161-180. PubMed ID: 30389579
[TBL] [Abstract][Full Text] [Related]
6. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.
Henderson BW; Gentry EG; Rush T; Troncoso JC; Thambisetty M; Montine TJ; Herskowitz JH
J Neurochem; 2016 Aug; 138(4):525-31. PubMed ID: 27246255
[TBL] [Abstract][Full Text] [Related]
7. The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice.
Izumi H; Shinoda Y; Saito T; Saido TC; Sato K; Yabuki Y; Matsumoto Y; Kanemitsu Y; Tomioka Y; Abolhassani N; Nakabeppu Y; Fukunaga K
Neuroscience; 2018 May; 377():87-97. PubMed ID: 29510211
[TBL] [Abstract][Full Text] [Related]
8. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
[TBL] [Abstract][Full Text] [Related]
9. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease.
Li L; Xu S; Liu L; Feng R; Gong Y; Zhao X; Li J; Cai J; Feng N; Wang L; Wang X; Peng Y
J Alzheimers Dis; 2017; 56(4):1403-1417. PubMed ID: 28157092
[TBL] [Abstract][Full Text] [Related]
11. Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages.
Serrano FG; Tapia-Rojas C; Carvajal FJ; Cisternas P; Viayna E; Sola I; Munoz-Torrero D; Inestrosa NC
Curr Alzheimer Res; 2016; 13(9):1017-29. PubMed ID: 26502813
[TBL] [Abstract][Full Text] [Related]
12. The Y
Matrone C; Iannuzzi F; Annunziato L
Ageing Res Rev; 2019 Jul; 52():120-128. PubMed ID: 31039414
[TBL] [Abstract][Full Text] [Related]
13. Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer's disease.
Batarseh YS; Kaddoumi A
J Nutr Biochem; 2018 May; 55():113-123. PubMed ID: 29413486
[TBL] [Abstract][Full Text] [Related]
14. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
Hwang SH; Shin EJ; Shin TJ; Lee BH; Choi SH; Kang J; Kim HJ; Kwon SH; Jang CG; Lee JH; Kim HC; Nah SY
J Alzheimers Dis; 2012; 31(1):207-23. PubMed ID: 22543851
[TBL] [Abstract][Full Text] [Related]
15. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study.
G V; S K; Sureshkumar ; G S; S S; Preethikrishnan ; S D; A S; D B; Riya ; P V
Biomed Pharmacother; 2018 Aug; 104():211-222. PubMed ID: 29775888
[TBL] [Abstract][Full Text] [Related]
17. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models.
Bignante EA; Ponce NE; Heredia F; Musso J; Krawczyk MC; Millán J; Pigino GF; Inestrosa NC; Boccia MM; Lorenzo A
Neurobiol Aging; 2018 Apr; 64():44-57. PubMed ID: 29331876
[TBL] [Abstract][Full Text] [Related]
18. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
19. An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies.
Deba F; Peterson S; Hamouda AK
Methods Mol Biol; 2019; 2011():393-412. PubMed ID: 31273712
[TBL] [Abstract][Full Text] [Related]
20. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease.
Xiang Y; Bu XL; Liu YH; Zhu C; Shen LL; Jiao SS; Zhu XY; Giunta B; Tan J; Song WH; Zhou HD; Zhou XF; Wang YJ
Acta Neuropathol; 2015 Oct; 130(4):487-99. PubMed ID: 26363791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
